Your browser doesn't support javascript.
loading
Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells.
Pickar-Oliver, Adrian; Black, Joshua B; Lewis, Mae M; Mutchnick, Kevin J; Klann, Tyler S; Gilcrest, Kylie A; Sitton, Madeleine J; Nelson, Christopher E; Barrera, Alejandro; Bartelt, Luke C; Reddy, Timothy E; Beisel, Chase L; Barrangou, Rodolphe; Gersbach, Charles A.
Affiliation
  • Pickar-Oliver A; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Black JB; Center for Advanced Genomic Technologies, Duke University, Durham, NC, USA.
  • Lewis MM; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Mutchnick KJ; Center for Advanced Genomic Technologies, Duke University, Durham, NC, USA.
  • Klann TS; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Gilcrest KA; Center for Advanced Genomic Technologies, Duke University, Durham, NC, USA.
  • Sitton MJ; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Nelson CE; Center for Advanced Genomic Technologies, Duke University, Durham, NC, USA.
  • Barrera A; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Bartelt LC; Center for Advanced Genomic Technologies, Duke University, Durham, NC, USA.
  • Reddy TE; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Beisel CL; Center for Advanced Genomic Technologies, Duke University, Durham, NC, USA.
  • Barrangou R; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • Gersbach CA; Center for Advanced Genomic Technologies, Duke University, Durham, NC, USA.
Nat Biotechnol ; 37(12): 1493-1501, 2019 12.
Article in En | MEDLINE | ID: mdl-31548729
Class 2 CRISPR-Cas systems, such as Cas9 and Cas12, have been widely used to target DNA sequences in eukaryotic genomes. However, class 1 CRISPR-Cas systems, which represent about 90% of all CRISPR systems in nature, remain largely unexplored for genome engineering applications. Here, we show that class 1 CRISPR-Cas systems can be expressed in mammalian cells and used for DNA targeting and transcriptional control. We repurpose type I variants of class 1 CRISPR-Cas systems from Escherichia coli and Listeria monocytogenes, which target DNA via a multi-component RNA-guided complex termed Cascade. We validate Cascade expression, complex formation and nuclear localization in human cells, and demonstrate programmable CRISPR RNA (crRNA)-mediated targeting of specific loci in the human genome. By tethering activation and repression domains to Cascade, we modulate the expression of targeted endogenous genes in human cells. This study demonstrates the use of Cascade as a CRISPR-based technology for targeted eukaryotic gene regulation, highlighting class 1 CRISPR-Cas systems for further exploration.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription, Genetic / Genetic Engineering / CRISPR-Cas Systems Limits: Humans Language: En Journal: Nat Biotechnol Journal subject: BIOTECNOLOGIA Year: 2019 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription, Genetic / Genetic Engineering / CRISPR-Cas Systems Limits: Humans Language: En Journal: Nat Biotechnol Journal subject: BIOTECNOLOGIA Year: 2019 Document type: Article Affiliation country: United States Country of publication: United States